Ornithine canon (Ornitin Canon)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceOrnithineOrnithine
Similar drugsTo uncover
  • Hepa-Mertz
    granules inwards 
    Merz Pharma GmbH & Co. KG. KGaA     Germany
  • Hepa-Mertz
    concentrate d / infusion 
    Merz Pharma GmbH & Co. KG. KGaA     Germany
  • Larnamine
    concentrate d / infusion 
    FARMAK, JSC     Ukraine
  • OrnilaTex®
    concentrate d / infusion 
    FarmSirma Soteks, ZAO     Russia
  • Ornithine
    granules inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Ornithine canon
    granules inwards 
    CANONFARMA PRODUCTION, CJSC     Russia
    • Dosage form: & nbspGranules for solution for oral administration
    Composition:Composition per package

    Active substance: L-Ornithine-L-Aspartate 3 g.

    Excipients: flavoring lemon 0,015 g, flavoring mint 0,005 g, aspartame 0,05 g, citric acid anhydrous 0,5 g, mannitol 1,430 g.

    Description:

    A mixture of granules and powder almost white or white with a yellowish tint of color with the smell of lemon and mint.

    Pharmacotherapeutic group:Hypoazotemic means
    ATX: & nbsp

    A.05.B.A.06   Ornithine oxoglurate

    Pharmacodynamics:

    Has a detoxification effect, reducing the elevated level of ammonia in the body, in particular, with liver diseases. The effect of the drug is associated with its participation in the ornithine cycle of urea formation Krebs (activates the cycle, restoring the activity of liver enzymes: ornithine carbamoyltransferase and carbamoyl phosphate synthase).

    Promotes the production of insulin and growth hormone. Improves protein metabolism in diseases requiring parenteral nutrition. Helps reduce asthenic, dyspeptic and pain syndromes, as well as normalization of increased body weight (with steatosis and steatohepatitis).

    Pharmacokinetics:

    L-ornithine-LAspartate rapidly dissociates into its constituent components - ornithine and aspartate, and begins to act for 15-25 minutes, with a short half-life. It is excreted in the urine through a cycle of urea formation.

    Indications:

    Acute and chronic liver disease, accompanied by hyperammonemia.

    Hepatic encephalopathy (latent and pronounced). Steatoses and steatohepatitis (of various origins).

    Contraindications:

    Severe renal failure with a creatinine score of more than 3 mg / 100 ml, hypersensitivity to the drug components, lactation period, children under 18 years of age (due to insufficient data).

    Carefully:Pregnancy.
    Pregnancy and lactation:

    The effect of the drug on pregnancy and lactation in humans has not been investigated. The drug should not be used during pregnancy, except in cases of extreme necessity, if the potential benefit to the mother significantly exceeds the potential risk to the fetus.

    The drug should not be used during breastfeeding. If therapy is necessary, breastfeeding should be discontinued.

    Dosing and Administration:

    Inside for 1-2 packets of granules dissolved in 200 ml of liquid, 2-3 times a day after meals. The course of admission depends on the severity of the disease.

    Side effects:

    The incidence of adverse reactions is represented by the following classification (classification of the World Health Organization): infrequently from> 1/1000 to <1/100, very rarely from <1/10000, including individual messages, frequency is unknown (the frequency can not be calculated by available data).

    Immune system disorders frequency unknown: allergic reactions.

    Disorders from the gastrointestinal tract infrequently: nausea, vomiting, abdominal pain, flatulence, diarrhea.

    Disturbances from musculoskeletal and connective tissue very rarely: pain in the limbs.

    Overdose:

    Symptoms: increased severity of side effects.

    Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

    Interaction:

    Not described.

    Special instructions:

    When the diagnosis is made, hepatic encephalopathy due to the underlying disease is necessaryto observe increased caution when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Effect on the ability to drive transp. cf. and fur:

    The drug Ornithine Canon does not affect the ability to drive vehicles or engage in other potentially hazardous activities.

    Form release / dosage:

    Granules for solution for oral administration, 3 g.

    Packaging:

    5 grams per package of combined material (paper / foil / polyethylene). For 10 or 30 packs, together with the instructions for use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-004148
    Date of registration:16.02.2017
    Expiration Date:16.02.2022
    The owner of the registration certificate:CANONFARMA PRODUCTION, CJSC CANONFARMA PRODUCTION, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp25.03.2017
    Illustrated instructions
      Instructions
      Up